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Materials and methods: Data from UNOS on all adults pan-
creas or kidney pancreas transplant recipients between 1996 and
2012 were analyzed. Venous extension grafts were used in 2,657;
they were not used in 18,124. Chi square test was used to
compare many of the standard categorical variables. The Mann-
Whitney test was used to compare the two groups for continuous
variables. Kaplan-Meier/Product-Limit Estimates and their cor-
responding 95% confidence intervals were computed. One, 3, 5,
10 and 15 year unadjusted patient and graft survival rates were
computed for both groups.
Results: Kaplan -Meier analysis demonstrated similar
patient survival (p < 0.641) and death censored graft survival
(p < 0.351) at 1, 3, 5, 10 and 15 years between subjects with
and without venous jump grafts.
Conclusion: The use of venous jump grafts is NOT associ-
ated with a higher risk of graft loss or patient death.
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MO-B.01 IS CHROMOGRANIN A
PROGNOSTIC FOR RESECTED
PANCREATIC NEUROENDOCRINE
TUMORS?
M. A. Shanahan, C. S. Cho, P. A. Rudnitzky, G. Leverson,
E. R. Winslow and S. M. Weber
University Of Wisconsin School Of Medicine & Public
Health, Madison, WI
Introduction: Previous studies have suggested prognostic
potential for the tumor marker chromogranin A (CgA) for
pancreatic neuroendocrine tumors (pNETs), but results to
date have been controversial. Our purpose was to explore the
clinical usefulness of preoperative CgA in predicting
outcome in patients with resected pNETs.
Methods: Patients who underwent resection of a pNET
from 2002–2013 and had a CgA level tested within 3 months
before surgery were identified from a prospective database.
An elevated preoperative CgA was defined as a CgA lab
value above the normal limit of the assay.
Results: A total of 38 patients met inclusion criteria, of
which 16 patients (42%) had elevated preoperative CgA. Of
these, 45% were male and the median age was 57 years
(range, 17–81). Operations included: 13 pancreaticoduo-
denectomies, 22 distal pancreatectomies, 1 central pancrea-
tectomy and 2 enucleations. There were no differences in
tumor size, node positivity, margin status, or tumor grade
between the two groups on univariate analysis. Both disease-
free survival (p = 0.008) and overall survival (p = 0.05) were
negatively impacted by an elevated preoperative CgA level
(median FU for surviving patients, 2.5 years). The only inde-
pendent predictor of DFS on multivariate analysis was
elevated preoperative CgA (HR 9.36, 90% CI 1.60–54.7,
p = 0.037). There were no independent predictors of OS.
Conclusion: In patients with resected pNETs, an elevated
preoperative CgA level was associated with decreased
disease-free and overall survival, and remained the only inde-
pendent predictor of DFS. Preoperative CgA appears to be a
clinically useful prognostic marker following resection of
pNET.
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MO-B.02 DETECTION OF SOMATIC
MUTATIONS IN DIAGNOSTIC FINE
NEEDLE ASPIRATES OF PANCREATIC
CANCER WITH NEXT-GENERATION
SEQUENCING
V. Valero1, T. J. Saunders2, R. H. Hruban1, J. L. Cameron1,
J. M. Herman3, C. A. Iacobuzio-Donahue1,2 and
C. L. Wolfgang1,2
1The Johns Hopkins University School Of Medicine,
Department Of Surgery, Baltimore, MD; 2The Johns
Hopkins University School Of Medicine, Department Of
Pathology, Baltimore, MD; 3The Johns Hopkins University
School Of Medicine, Department Of Radiation Oncology,
Baltimore, MD
A personalized approach to the treatment of pancreatic cancer
that is based on genetic status depends on tissue for genetic
analysis. Fine needle aspiration (FNA) is the most commonly
used method for obtaining tissue prior to surgical resection.
Potentially limiting factors of FNA include the paucity of malig-
nant cells within a fibroblast-rich stroma and tumor heterogene-
ity. Therefore, we sought to determine: the ability to confidently
detect mutant alleles in low cellularity samples, the concordance
between the FNA and the primary tumor and the feasibility of
identifying driver mutation in clinical FNAs.
Methods: We determined the ability to detect cancer-
specific mutations in a wild-type stromal background in an in
vitro model of Panc1 cells diluted into the fibroblast cell line,
CAF 35, and the genotypic concordance between FNAs and
their matched resected human adenocarcinoma tissues using
next-generation sequencing. Finally, the feasibility of driver
mutation identification via FNA was explored by sequencing
clinical FNA samples.
Results: The limit of confident detection occurred at a 1 : 25
ratio of malignant to stromal cells for both the KRAS and
TP53 mutant alleles corresponding to a hypothetical carci-
noma with 4% neoplastic cellularity. The concordance
between the FNA and tumor samples ranged from 83% to
100%, although there was 100% concordance for driver muta-
tions in all samples. Sequencing of clinical FNAs revealed
driver mutations of KRAS, TP53 and SMAD4 genes.
Conclusion: Confident genotyping of low cellularity FNA
samples is possible and accurately detects the driver muta-
tions in primary tumors thus allowing the potential for per-
sonalized patient care.
MO-B.04 COMPARISON OF ROBOT
VERSUS OPEN
PANCREATICODUODENECTOMY
B. A. Boone1, S. Downs-Canner1, J. Steve1, M. S. Zenati1,
M. E. Hogg1, A. J. Moser2, D. L. Bartlett1, H. A. Choudry1,
H. J. Zeh1, A. H. Zureikat1
1Department Of Surgery, University Of Pittsburgh,
Pittsburgh, PA; 2Department Of Surgery, Beth Israel
Deaconess Medical Center, Boston, MA
Introduction: The safety, feasibility and learning curve of
robotic pancreaticoduodenectomy (RPD) has been demon-
strated, however data comparing large series of RPD to open
pancreaticoduodenectomy (OPD) is lacking. Therefore, we
sought to compare outcomes of RPD to OPD.
Methods: A prospectively-maintained database of consecu-
tive patients undergoing RPD from 2008–2013 was analyzed
and compared to consecutive OPD cases performed from
2007–2008 (prior to robot utilization). Patients with border-
line resectable disease were excluded. Additionally, the pre-
viously identified learning curve for RPD of 80 patients was
excluded, ensuring the optimization of outcomes in both
groups.
Results: Demographics and outcomes of 58 RPD patients
were compared with 98 patients undergoing OPD. There
were no significant differences in age, gender, BMI, number
of patients with prior abdominal surgery, Charlson
Comorbidity Index, ASA, pathologic indication, malignancy,
tumor size or Ca 19-9 between groups. Peri-operative out-
comes are shown in Table 1. RPD was associated with sig-
nificantly lower blood loss, higher lymph node yield, and
lower incidence of pancreatic leak. There was a trend toward
slightly longer operative time in the RPD group that did not
reach statistical significance.
Conclusion: Beyond its initial learning curve, RPD is asso-
ciated with outcomes comparable to open resection. In this
series, RPD was associated with improved operative blood
loss, pancreatic leak rate, and lymph node harvest compared
with ODP. Further study of RPD, potentially including a
multi-institutional comparison to OPD, is warranted.
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MO-B.05 GENERAL SURGERY RESIDENT
PARTICIPATION IN COMPLEX
PANCREATIC PROCEDURES
Y. Tilahun1, P. Veldhuis1, S. Eubanks1, P. Arnoletti1,2 and
S. G. De La Fuente1,2
1Florida Hospital Orlando, Orlando, FL; 2University Of
Central Florida, Orlando, FL
Background: Growing concerns exist regarding compe-
tence of general surgery (GS) residents in complex pancre-
atic procedures as more HPB-focused fellowships become
available. This limited experience may be associated with
worse patient outcomes. We analyzed postoperative out-
comes in patients that underwent complex pancreatic sur-
geries with the participation of GS residents.
Methods: Data from the NSQIP-PUF from 2011 was used
to assess association between resident participation and post-
operative outcomes. The primary variables measured were
30-day postoperative mortality, overall complication rate,
serious complication rate, and length of stay (LOS).
Results: Of the 2,156 surgeries identified, GS residents par-
ticipated in 85% (n = 1,839) of cases. Standard pancreatico-
duodenectomy was the most common procedure (n = 682,
37%), followed by distal pancreatectomy (n = 458, 25%),
and pylorus-preserving pancreaticoduodenectomy (n = 335,
18%). Distribution of cases was similar in the no-resident
group. Patient demographics were similar between groups,
although more patients in the resident group had CHF, PVD,
TIAs, and bleeding disorders. Both anesthesia (no-resident
385 ± 186 min vs. resident 406 ± 163 min, p = 0.019) and
operative times (no-resident 311 ± 172 min vs. resident
331 ± 151 min, p = 0.019) were longer in resident-assisted
cases. No differences in overall complication rate, serious
complications or mortality rates were found between groups,
although LOS was longer for those patients without GS
residents.
Conclusion: Participation of GS residents in complex pan-
creatic procedures is associated with longer anesthesia and
operative times. This increment in times does not result in
higher early postoperative morbidity or mortality.
MO-B.06 DIAGNOSTIC LAPAROSCOPY
SHOULD BE PERFORMED BEFORE
DEFINITIVE RESECTION FOR
PANCREATIC CANCER: A FINANCIAL
ARGUMENT
T. T. Jayakrishnan1, H. Nadeem1, R. T. Groeschl1,
B. George1, J. P. Thomas1, P. S. Ritch1, K. K. Christians1,
S. Tsai1, D. B. Evans1, S. G. Pappas2, T. C. Gamblin1 and
K. K. Turaga1
1Medical College Of Wisconsin, Milwaukee, WISCONSIN;
2Loyola University Medical Center, Maywood, ILLINOIS
Objective: To study the cost-effectiveness of routine diag-
nostic laparoscopy (DL) at the time of definitive resection for
pancreatic cancer (PC) in the surgery-first (SF-PC) and
neoadjuvant therapy paradigms (NAT).
Background: Laparoscopy is recommended to detect
radiographically-occult extra-pancreatic disease in patients
with localized pancreatic cancer to prevent non-therapeutic
laparotomy. There is concern that the selection process of
neoadjuvant therapy and repeated imaging may make routine
laparoscopy unnecessary. We hypothesized that DL remains
cost effective in patients who undergo pancreatectomy
treated with the neoadjuvant approach.
Methods: Decision tree modeling compared routine DL
versus exploratory laparotomy (ExLap) at the time of cura-
tive resection for – (i) SF-PC setting, and (ii) borderline
resectable PC (BR-PC) in the NAT setting. Costs (US$) from
payers’ perspective, quality-adjusted-life-months (QALMs)
and incremental-cost-effectiveness-ratios (ICER) were cal-
culated. Base case estimates and multi-way sensitivity-
analyses were performed. The willingness-to-pay (WTP)
was $4,166/QALM (or $50,000/QALY).
Results: The base-case costs were $34,921 for ExLap vs.
$33,441.74 for DL in the SF-PC setting; and $39,633 ExLap
vs. $39,713 DL in BR-PC. Routine laparoscopy is the domi-
nant (preferred) strategy in the surgery first approach (cost
reduction of $10,695/QALM) and in borderline resectable
patients treated with neoadjuvant therapy (additional cost of
$4,158/QALM which is lower than the willingness-to-pay of
$4,166/QALM).
Conclusion: Our analysis supports the cost-effectiveness of
routine diagnostic laparoscopy before curative resection of
pancreatic cancer patients treated either with surgery first or
neoadjuvant approach.
MO-B.07 THE EFFECT OF MARGIN
STATUS ON SURVIVAL FOLLOWING
PANCREATICODUODENECTOMY
D. J. Niemeyer, R. M. Seshadri, R. Z. Swan, D. Sindram,
R. Nazemzadeh, J. B. Martinie and D. A. Iannitti
Carolinas Medical Center, Charlotte, NC
Introduction: Pancreaticoduodenectomy (PD) is a key
component of the multidisciplinary treatment of pancreatic
adenocarcinoma. Margin status of the resection remains a
controversial subject, with some small studies demonstrating
no difference in survival between margin negative (R0)
resections and microscopically positive (R1) resections. The
current study aims to compare survival of patients with stage
II and stage III pancreatic cancers depending on resection
margin status.
Methods: The Commission on Cancer’s National Cancer
Database (NCDB) is a registry of 342,267 patients diagnosed
with pancreatic cancer from 1998–2011. Demographic,
cancer related, and treatment related data are available for all
patients. Survival data is available before 2007.
Results: A total of 27,818 PD were performed for adeno-
carcinoma between 1998–2011. Survival data was available
for 16,925, of which 2,582 were identified as clinical stage II
or stage III disease. A large number of patients did not have
pre-op staging information. Overall survival for stage II
disease was significantly higher with R0 compared with R1
resections (median 18.99 vs. 12.98 months, p < 0.0001).
There was no statistically significant survival difference
between R0 and R1 resections for Stage III disease (median
15.44 vs 14.59 months, p = 0.1017).
Conclusion: The NCDB provides the opportunity to
examine a large number of PD patients in a multi-
institutional retrospective manner. Survival of stage II pan-
creatic adenocarcinoma after a PD is negatively affected by
margin status. Survival of stage III disease, defined by
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involvement of large vessels, is unaffected by microscopi-
cally positive surgical margins.
MO-B.08 NEOADJUVANT RADIATION IS
EQUIVALENT TO ADJUVANT
RADIATION FOLLOWING
PANCREATICODUODENECTOMY FOR
STAGE II AND III ADENOCARCINOMA
D. J. Niemeyer, R. M. Seshadri, R. Z. Swan, D. Sindram,
A. J. Crimaldi, J. B. Martinie and D. A. Iannitti
Carolinas Medical Center, Charlotte, NC
Introduction: The use of radiation therapy for treatment of
pancreatic adenocarcinoma is well established in the US. The
timing of treatment relative to pancreaticoduodenectomy
(PD), either as neoadjuvant (NR) or adjuvant radiation(AR)
is debated. The current study aims to compare survival of
patients with stage II and stage III adenocarcinoma depend-
ing on the use and timing of radiation therapy.
Methods: The Commission on Cancer’s National Cancer
Database (NCDB) is a registry of 342,267 patients diagnosed
with pancreatic cancer from 1998–2011. Demographic,
cancer specific, and treatment related data are available for
all patients. Survival data is available before 2007.
Results: 27,818 PD were performed for adenocarcinoma
from 1998–2011. Survival data is available for 16,925, of
which 2,582 were identified as clinical stage II or III, with
many having no pre-op staging information. 130 stage II
patients underwent NR, 674 received AR. 81 stage III
patients received NR, while 266 received AR. For stage II
and III disease, any form of radiation improved survival
significantly compared with no radiation (Stage II no rad/any
rad 13.8/20.47 months p < 0.0001, stage III no rad/any rad
9.79/17.05 months p < 0.0001). Comparison of NR to AR
was insignificant for stage II and III disease (stage II NR/AR
24.44/20.24 months p = 0.0689, stage III NR/AR 19.09/
16.46 months p = 0.4030).
Conclusion: The use of radiation as an adjunct to surgical
resection significantly improves overall survival in pancre-
atic cancer. Analysis of the large number of patients in the
NCDB demonstrate no significant survival benefit of NR
when compared to AR in stage II and stage III disease.
MO-B.09 RISK FACTORS FOR
PANCREATIC FISTULA AFTER ROBOTIC
PANCREATICODUODENECTOMY
P. M. Polanco, M. E. Hogg, M. Shakir, M. S. Zenati,
M. Choudry, B. A. Boone, D. L. Bartlett, H. Zeh and
A. H. Zureikat
Division Of Surgical Oncology, University Of Pittsburgh
Medical Center, Pittsburgh, PA
Background: Prognostic scores predicting post-operative
pancreatic fistulas (POPF) have been reported and validated
for open pancreaticoduodenectomy (OPD). However, no
reports have outlined the risk factors of POPF in robotic
pancreaticoduodenectomy (RPD). Our objectives were to
identify independent risk factors for POPF in patients under-
going RPD and to validate the prognostic scores previously
described for OPD.
Methods: A prospectively-maintained single institutional
database of patients that underwent RPD (2008–2013) was
analyzed. POPF was classified according to ISGPF criteria.
Demographics and peri-operative outcomes where compared
in patients with and without POPF. Univariate and multivari-
ate analysis (UVA/MVA) with logistic regression modeling
was used to identify independent variables for POPF. Braga
and Callery scores were calculated and tested with logistic
regression analysis.
Results: 150 consecutive RPDs were analyzed. POPF
occurred in 26 (17.3%); 13 (8.6%) of which were ISGPF
category B and C. On UVA, patients with POPF had larger
body mass index (BMI), smaller duct, smaller tumor size,
longer OR time, larger estimated blood loss (EBL) and RBC
transfusion (all p < 0.05). On MVA, EBL, small duct size,
larger BMI and small tumor size remained the best independ-
ent risk factors for POPF after RDP (all p < 0.001). Increased
Callery (OR: 1.520, 95% CI: 1.065–1.608, p = 0.01) and
Braga (OR: 1.2, 95% CI: 1.064–1.430, p = 0.005) scores
predicted an increased risk of POPF following RPD.
Conclusion: In this series of RPD, incidence of POPF was
similar to that reported for historical OPD. Larger BMI,
higher EBL, smaller tumor size, and smaller duct are the
main predictors of POPF in RPD. Callery and Braga scores
have predictive value for POPF in RPD.
Abstracts 93
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary AssociationHPB 2014, 16 (Suppl. 1), 1–99
MO-B.10 IN-HOSPITAL MORTALITY
FOLLOWING
PANCREATICODUODENECTOMY
J. He, M. Weiss, J. Cameron, N. Ahuja, K. Hirose,
T. Pawlik and C. Wolfgang
Department Of Surgery, Johns Hopkins Medical
Institutions, Baltimore, MD
Introduction: This aim of this study is to investigate causes
of in-hospital mortality after pancreaticoduodenectomy in a
single institution.
Methods: We reviewed clinical data of 3890 consecutive
patients who underwent pancreaticoduodenectomy from
1990 to 2011. In-hospital mortality was defined as death
during the index admissions for pancreaticoduodenectomy.
Patients who survived the index admission were used as
comparison.
Results: The demographics and the median Charlson Age-
Comorbidity Index (CACI) were summarized in Table 1. The
distribution of pathology was similar in two cohorts. The
overall in-hospital mortality was 1.6% (61 of 3890). Two
patients died during the pancreaticoduodenectomy due to
severe bleeding and cardiac arrest, while the other 59 died at
a median of 18 days (range 0–120). In-hospital mortality
cohort is older than other cohort (p < 0.001). It had higher
rate of complications such as pancreatic fistula, postop bleed-
ing, sepsis related liver failure, bowel ischemia, vascular
occlusion related liver failure, abdominal compartment syn-
drome and myocardium ischemia (p < 0.001). The percent-
age of patients underwent vascular resections or repair or
redo exploratory laparotomy was also significantly higher
(p < 0.001). Incidence of in-hosptial mortality in 1990s was
similar to that in 2000s (1.8% vs 1.4%, p = 0.36).
Conclusion: Although causes for in-hospital mortality are
multifactorial, pancreatic fistula and vascular complication
related ischemia are highly associated with in-hospital
mortality.
MO-B.11 HOSPITAL READMISSION
AFTER PANCREATICODUODENECTOMY
IN A HIGH VOLUME CENTER
J. Rose, F. B. Rocha, A. Alseidi, T. B. Biehl and S. Helton
Virginia Mason Medical Center, Seattle, WASHINGTON
Background: Thirty day hospital readmission is a new
quality metric that will be used to reduce hospital reimburse-
ment in the future. The aims of this study were to identify
predictors of readmission following pancreaticoduo-
denectomy and to estimate health care resource dollars saved
from avoidable readmission.
Methods: The electronic medical record and hospital finan-
cial database were utilized to retrospectively identify all
patients undergoing pancreaticoduodenectomy between
2008 and 2012 in a high-volume tertiary hospital. Patient
demographics, hospital charges, perioperative outcomes, and
discharge disposition were determined. Readmission rate,
corresponding etiologies, and associated charges were estab-
lished. Predictors of readmission were determined by multi-
variate logistic regression.
Results: Of the 380 patients that underwent pancreaticoduo-
denectomy between 2008 and 2012, 69 (18%) were readmit-
ted within 30 days (median 7 days). Readmissions accounted
for an additional 458 hospital days (median 5 days per read-
mission). Age, gender, Charlson comorbidity index, opera-
tive indication, length-of-operation, length-of-stay, discharge
disposition, payer status, or hospital charges were not pre-
dictive of readmission. However, having a complication prior
to discharge was a risk factor [OR 2.5 (1.5–4.3); p = <0.001].
Hospital mortality and complication rates were 0.5% and
32% respectively. The most common causes for readmission
were: infection (52%), gastrointestinal-related (16%), dehy-
dration (10%), and pain (3%). Twelve readmissions (17%)
were determined to be avoidable, accounting for 65 addi-
tional hospital days and associated charges totaling
$231,000.
Discussion: Early identification of patients at risk for avoid-
able readmission following pancreaticoduodenectomy has
great potential to reduce health care expenditures in high
volume hospitals performing these complex operations.
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MO-B.12 QUANTITY AND QUALITY: A
HIGH VOLUME PANCREATIC CENTERS
ADHERENCE TO HIGHLY VALIDATED
QUALITY MEASURES OF PANCREATIC
CANCER CARE
M. Ongchin, J. Steve, D. Bartlett, M. Choudry, K. Lee,
W. Marsh, A. Tsung, A. Zureikat, H. Zeh and M. Hogg
University Of Pittsburgh, Pittsburgh, PA
Background: Despite extensive data demonstrating
improved outcomes at high volume pancreatic centers, little
data examines the heterogeneity amongst institutions.
Bilimoria et al developed 50 quality indicators (QI) address-
ing 5 domains in pancreatic cancer care (PCC). Despite
the availability of these validated metrics since 2009, few
centers report their performance. We examined our instit-
ution’s compliance with these PCC QI, hypothesizing that
tracking these measures would be feasible and assure high
compliance.
Methods: We analyzed a prospectively maintained Pancre-
atic Quality Improvement database specifically used to track
these QI between 4/2011–7/2013.
Results: 570 patients were captured, 322 had pancreatic
adenocarcinoma: 125 resectable, 25 locally advanced, 172
metastatic. We were >90% compliant with 42/43 of the vali-
dated QI. Compliance on QI #26 was 86% (table). In patients
with >60days to treatment, 55% were metastatic contemplat-
ing therapy. Median time from diagnosis to surgery was
24days. 67% received neoadjuvant therapy; median time to
treatment (MTTT) was 22days. 74% received adjuvant
therapy; MTTT was 51days. Surgical outcomes were 2.2%
peri-operative mortality, 85% R0 resection, 20.5 median
lymph nodes, 350 cc median EBL, 459 min median OR time,
and 34% readmission. 26% enrolled in one of 11 clinical
trials. Our composite score was 9/10 (median = 4 in
Bilimoria’s study). The QI database is maintained by 1/5
FTE (8 hrs/wk).
Conclusion: Our high volume Pancreatic Center complied
with 98% of highly validated QI. Time maintaining this data-
base is feasible, prospectively tracking PCC performance.
Institutions performing pancreatic surgery should track and
report these indicators as part of their quality measures of
outcomes.
MO-B.13 TUMOR STAGE AT
PRESENTATION AND ACCESS TO
SURGERY IS NOT INFLUENCED BY
RACE IN PANCREATIC CANCER
PATIENTS
Y. Tilahum1, X. Zhu1, S. Litherland1, P. Veldhuis1,
D. A. Decker1, S. Eubanks1, A. Simmonds1,2, P. Arnoletti1,2
and S. G. De La Fuente1,2
1Florida Hospital Orlando, Orlando, FL; 2University Of
Central Florida, Orlando, FL
Background: Previous studies have shown race-dependent
disparities in oncologic outcomes among patients with pan-
creatic cancer. Proposed explanations include differences
in access to care, socioeconomic status, education level,
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religious factors, and availability of social support. We
analyzed the influence of race in tumor stage at presentation
and access to surgery in a large ethnically diverse patient
population from the state of Florida.
Methods: A prospectively maintained tumor registry of all
patients with pancreatic cancer treated at the FloridaAdventist
Health System from 2001 to 2012 was queried. Outcome
variables included tumor stage at presentation and percentage
of patients that underwent surgical treatment during the study
period. Comparison groups were divided by race and gender.
Results: A total 812 patients were seen with pancreatic
cancer within the studied period. The majority of patients
were Caucasian (Table). There were no significant differ-
ences in race (p = 0.81) or gender (p = 0.16) associated
tumor stage at presentation. Additionally, a similar number of
patients underwent surgical treatment within the different
ethnicities (Caucasian 22.3%; Hispanics 22.8%; African-
American 18.3%, p = 0.70).
Conclusion: Despite previous reports showing differences
in overall survival rates, stage at presentation and access to
surgery appear to be similar between races in a large ethni-
cally diverse -pancreatic cancer patient population.
MO-B.15 PANCREATECTOMY IN
PATIENTS ON CHRONIC DIALYSIS: IS IT
TOO RISKY?
S. W. Cho and J. S. Cardinal
Department Of Surgical Oncology, West Virginia
University Hospitals, Morgantown, WV
Introduction: Need for dialysis treatment is a significant
co-morbidity that may exclude patients from pancreatec-
tomy. However, its impact on surgical morbidity and mortal-
ity has not been well defined. We sought to quantify
complication rates of pancreatectomy in patients on chronic
dialysis.
Method: Database from the American College of Surgeons
National Surgical Quality Improvement Project (ACS-
NSQIP) (2005–2011) was queried to identify patients on
dialysis. Those with acute renal failure or undergoing emer-
gent surgery were excluded. CPT codes were used to select
pancreatectomy cases.
Results: There were 32800 patients who were on dialysis
before surgery. A total of 63 pancreatectomies were per-
formed for patients on dialysis (pancreaticoduodenectomy
(n = 34), distal or subtotal pancreatectomy (n = 25) or total
pancreatectomy (n = 4)). Median age was 63. Indications
were pancreatic cancer (n = 17), peri-ampullary tumor
(n = 8), neuroendocrine tumor (n = 5), other malignancy
(n = 6), benign pancreatic tumor (n = 6) and other benign
diseases (n = 21). Median length of hospital stay was 9 days.
Overall morbidity and mortality were 42.9 and 4.8%, respec-
tively. Morbidity rates were 52.9, 36.0 and 0% for
pancreaticoduodenectomy, distal or subtotal pancreatectomy
and total pancreatectomy, respectively. Major post-operative
complications included sepsis (20.6%), blood transfusion
(15.9%), deep organ space infection (14.3%), re-operation
(6.3%), and cardiac arrest (3.2%). In addition, failure to wean
ventilation (20.6%) and re-intubation (11.1%) rates were
significant.
Conclusion: This is the largest reported series of patients on
chronic dialysis undergoing pancreatectomy. In carefully
selected cases, pancreatectomy can be performed with less
than 5% mortality rates. However, particular attention needs
to be paid for post-operative respiratory function.
MO-B.16 ADJUVANT CHEMOTHERAPY
PROVIDES BETTER OVERALL
SURVIVAL AFTER RADICAL RESECTION
FOR PANCREATIC ADENOCARCINOMA
S. Hurton, F. MacDonald, S. Ayloo and M. Molinari
Dalhousie University , Halifax, NS
Objectives: The expected overall survival (OS) of patients
undergoing radical resection for pancreatic adenocarcinoma
(PC) is in the range of 10–20%. Several randomized con-
trolled trials comparing adjuvant chemotherapy (AC) versus
surgery alone (SA) have shown conflicting results. This study
aimed to conduct a systematic review of the literature and
perform a meta-analysis (if appropriate) of the effect of AC
vs. SA on the OS of patients undergoing radical pancreatic
resections.
Methods: Seven electronic databases were searched using
standard technique to August 2013 without restriction on
publication status or language. The primary aim was to
assess the pooled effect of AC on the OS after pancreatic
resections. A random-effects model was used for the meta-
analysis as significant heterogeneity among the included
studies was identified (I2 53.2, P = 0.029).
Results: Nine Phase III RCTs were included (publication
years: 1993–2012). Analysis for publication bias did not
show any significant unbalance (Funnel Plot; Figure 1). A
total of 665 patients were randomized to AC after surgery
while 652 patients were randomized to SA (Table1). Pooled
data showed that AC provides a significant OS benefit in
comparison to SA: Odds Ratio 0.591 (95% CI 0.388–0.900;
P = 0.014) (Forest Plot, Figure 2).
Conclusion: The administration of AC provides a signifi-
cant improvement for the OS of patients undergoing radical
PC resections and should be recommended to all patients
irrespective of TNM status of their primary disease. Figure 1:
Funnel plot Figure 2: Forest plot Table 1: Summary of all the
randomized controlled studies included in the metanalysis.
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MO-B.17 LEARNING CURVE FOR
ROBOTIC DISTAL PANCREATECTOMY
M. Shakir, M. Khreiss, P. M. Polanco, B. A. Boone,
M. Zenati , M. Hogg, M. H. Choudry, D. L. Bartlett,
H. Zeh and A. H. Zureikat
University Of Pittsburgh Medical Center, Pittsburgh, PA
Background: Robotic Distal Pancreatectomy (RDP) has
been reported as equivalent or superior to laparoscopic distal
pancreatectomy and is being performed with increasing fre-
quency, however no data on how many cases are required to
attain clinical proficiency has been reported. Understanding
the “learning curve” would facilitate dissemination and
adoption of this innovative surgical approach. We hypoth-
esized that we could identify inflexion points and plateaus in
important metrics of surgical outcomes that correspond to
maximal efficiency.
Methods: We evaluated metrics of peri-operative safety and
efficiency in our prospectively maintained database of RDP.
Patients with involvement of the spleno-portal junction or
concomitant involvement of other organs were excluded.
Patients were divided chronologically into 8 groups of 12
patients each for analysis. ANOVA, Kruskal Wallis, and
Fisher Exact tests were used in comparing the groups.
Results: 100 patients underwent RADP from 1/2008 to
8/2013 with no 30-day mortality. Average age was 59.7 years.
The 8 groups demonstrated equivalent demographics, BMI,
Charlson Co-morbidity index, tumor size and pathology. 68
patients (70.8%) underwent resection for malignancy. There
were 2 conversions to an open operation (2 %). Operative time
reduced significantly after the first 36 patients from 303
minutes to 215 minutes (p < 0.001). The rate of administration
of blood transfusion declined after 24 patients (p < 0.05). No
significant trend was noted for conversion rate, operative
blood loss, margin positivity and length of stay in the hospital.
Conclusions: RDP is safe and feasible, with low 90-day
morbidity and no 30-day mortality. Reduction in operative
times plateau after 36 cases.
MO-B.18 OBESITY IS AN INDEPENDENT
PREDICTOR OF BILE DUCT INJURIES IN
PATIENTS UNDERGOING
CHOLECYSTECTOMY
H. Aziz, A. Amini, V. Pandit, T. Jie and E. Ong
University Of Arizona, Tucson, AZ
Introduction: Iatrogenic bile duct injury is a serious com-
plication of cholecystectomy. The aim of this study was to
assess predictors of bile duct injury using a national database.
Methods: The Nationwide Inpatient Sample (2009) was
queried for cholecystectomy. We used a) diagnoses for bile
duct injury and b) bile duct injury repair procedure codes
(51.36, 51.37, 51.39, 51.71, 51.72, and 51.79) as a surrogate
marker for bile duct injuries.
Results: A total of 56 patients had bile duct injury. The
mean age was 58.2 ± 19.7 years, 53.5% were males, and
median Charlson co-morbidity score was 2 [2–3]. Multivari-
ate analysis revealed Obesity (2.8[2.1–4.3]; p-0.03) and
emergent cholecystectomy (1.2 [1.1–1.6]; p-0.01) as the
independent predictors for bile duct injury in patients under-
going cholecystectomy. Sub-analysis, revealed that obese
patients undergoing emergent cholecystectomy were 1.8
folds more likely to have bile duct injury as compared to
obese patients with elective cholecystectomy (1.8 [1.45–
2.1]).
Results: Our study finds a new association between the
obesity and bile duct injuries which has never been reported
in literature before. The effect of obesity on outcomes in
biliary surgery needs prospective evaluation.
MO-B.19 A SYSTEMATIC REVIEW AND
META-ANALYSES OF HEPATIC ARTERY
BASED THERAPIES FOR
UNRESECTABLE INTRAHEPATIC
CHOLANGIOCARCINOMA
L. Boehm, T. Thayyil Jayakrishnan, J. Miura,
K. K. Turaga, F. M. Johnston, S. Tsai and T. C. Gamblin
Medical College Of Wisconsin Department Of Surgery,
Milwaukee, WI
Introduction: Hepatic artery based therapies (HAT) are
offered for patients with intrahepatic cholangiocarcinoma
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(ICC) that often present as unresectable. The present study is
a systematic review and meta-analyses of the comparative
effectiveness of HAT – hepatic arterial infusion (HAI),
transcatheter arterial chemoembolization (TACE), drug-
eluting bead TACE (DEB-TACE), and Yttrium90
radioembolization (Y90) for unresectable ICC.
Methods: A prospectively registered study protocol
(PROSPERO ID – CRD42013004830) utilized specific key
words to find peer-reviewed, English articles from PubMed
(1990–2013). Eligible articles based on predetermined
inclusion-exclusion criteria were used for data extraction.
Primary outcome was median overall survival (OS), and sec-
ondary outcome was tumor response to therapy (RECIST).
Results: Of the 793 articles identified by the search, 20 were
selected for data extraction (n = 627 patients). Complete
tumor response was reported in two patients (one TACE and
one DEB-TACE). Partial response to therapy was highest
with HAI (41.3%, range 12–100%, n = 63) vs. DEB-TACE
(32.4%, range 4.2–90%, n = 34) vs.Y90 (26.4%, range 10.5–
35.3%, n = 121) vs. TACE (12.6%, range 0–45%, n = 333).
Incidence of disease progression was lowest after HAI
(12.7%, 3.8–20%) vs. Y90 (14.9%, 4.5–21.7%) vs. DEB-
TACE (20.6%, 0–29.1%) vs. TACE (25.5%, 0–75%).
Highest Median OS was observed for HAI (21, 11–31)
months vs. Y90 (14, 9–22) months vs. TACE (13, 6–16)
months vs. DEB-TACE (12, 12–13) months.
Conclusion: For patients with unresectable ICC treated
with hepatic artery based therapies, hepatic arterial infusion
(HAI) offers best outcomes in terms of tumor response and
overall survival. Cost-effectiveness and optimization by
patient-disease characteristics are a focus for future research.
MO-B.20 HOSPITAL READMISSIONS
RATES FOLLOWING OPEN AND
LAPAROSCOPIC CHOLECYSTECTOMY
L. Watkins1, P. Veldhuis 1, S. Eubanks1, P. Arnoletti1,2 and
S. G. De La Fuente1,2
1Florida Hospital Orlando, Orlando, FL; 2University Of
Central Florida, Orlando, FL
Background: The introduction of laparoscopic techniques
has radically changed the management of patients with
benign biliary conditions over the past two decades. Well-
documented benefits of minimally invasive approaches
include decreased postoperative pain, early discharge from
the hospital and quicker initiation of normal activity. Limited
data however exists regarding readmission rates following
laparoscopic cholecystectomy. In this study, we determined
readmission rates over a 3-year period using a large national
database.
Methods: The National Impatient Sample was queried for
patients requiring readmissions 30-days after discharged for
the years 2009, 2010 and 2011. Patients were identified based
on diagnostic related groups (DRG) associated with both
open and laparoscopic cholecystectomy (414–419). Read-
mission percentages are defined as the percentage of index
stays with at least one readmission within 30 days of dis-
charge. Costs reflect the actual costs of care and not the
charges the hospital billed for a case.
Results: A total 99,842 patients that underwent open chol-
ecystectomy were discharged during the study period, while
889,914 were discharged after undergoing a laparoscopic
cholecystectomy. Thirty-day readmission rates were signifi-
cantly higher in the open group compared to the laparoscopic
group (open n = 10,870 [10.8%] vs. laparoscopic n = 65,917
[7.4%], p < 0.0001). The average cost per readmission for
patients that underwent an open cholecystectomy was
$12,789 compared to $11,073 for patients within the
laparoscopic group (p < 0.0001). Readmission rates within
the analyzed years remained the same.
Conclusion: Although lower than open cholecystectomy,
readmission rates following laparoscopic cholecystectomy
are relative common. Readmissions following cholecystec-
tomy are associated with substantial costs.
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